Zelira Therapeutics (ASX:ZLD) Beginning Cash Position: A$1.19 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zelira Therapeutics Beginning Cash Position?

Zelira Therapeutics ASX:ZLD Beginning Cash Position is A$1.19 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

Zelira Therapeutics's Beginning Cash Position for the quarter that ended in Jun. 2025 was A$1.19 Mil.

Zelira Therapeutics's quarterly Beginning Cash Position declined from Jun. 2024 (A$0.82 Mil) to Dec. 2024 (A$0.59 Mil) but then increased from Dec. 2024 (A$0.59 Mil) to Jun. 2025 (A$1.19 Mil).

Zelira Therapeutics's annual Beginning Cash Position declined from Jun. 2023 (A$2.75 Mil) to Jun. 2024 (A$-0.02 Mil) but then increased from Jun. 2024 (A$-0.02 Mil) to Jun. 2025 (A$0.59 Mil).

Zelira Therapeutics Beginning Cash Position Related Terms

Zelira Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Beginning Cash Position Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.70 4.97 2.75 -0.02 0.59

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.90 0.15 0.82 0.59 1.19

Zelira Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of A$1.19 Mil mean?
Zelira Therapeutics (ASX:ZLD) has a Beginning Cash Position of A$1.19 Mil as of Jun. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Beginning Cash Position too high?
Zelira Therapeutics' current Beginning Cash Position is A$1.19 Mil.
How does Zelira Therapeutics' Beginning Cash Position compare to MTNB and SXTP?
Zelira Therapeutics' Beginning Cash Position of A$1.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Beginning Cash Position is A$1.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Beginning Cash Position of A$1.19 Mil. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Beginning Cash Position is A$1.19 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Beginning Cash Position is A$1.19 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.